Imunon Inc. (IMNN)
0.89
-0.00 (-0.39%)
At close: Jan 15, 2025, 3:59 PM
0.90
1.65%
After-hours Jan 15, 2025, 04:27 PM EST
undefined% (undefined)
| Bid | 0.88 |
| Market Cap | 12.83M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.91 |
| PE Ratio (ttm) | -0.46 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.91 |
| Volume | 91,715 |
| Avg. Volume (20D) | 276,742 |
| Open | 0.91 |
| Previous Close | 0.89 |
| Day's Range | 0.87 - 0.91 |
| 52-Week Range | 0.48 - 3.65 |
| Beta | undefined |
About IMNN
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has t...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 1, 1999
Employees 33
Stock Exchange NASDAQ
Ticker Symbol IMNN
Website https://www.imunon.com
Analyst Forecast
According to 3 analyst ratings, the average rating for IMNN stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 3176.84% from the latest price.
Buy 66.67%
Hold 0.00%
Sell 0.00%
5 months ago ·
Source
-11.44%
Imunon shares are trading lower. The company repor...
Unlock content with
Pro Subscription
5 months ago ·
Source
-59.34%
Imunon shares are trading lower after the company announced a $10M registered direct offering of 5M shares of common stock with unregistered warrants at a price of $2 per unit.
